We are live on ! Find out more
JANX icon

Janux Therapeutics
JANX

155 hedge funds and large institutions have $1.87B invested in Janux Therapeutics in 2024 Q2 according to their latest regulatory filings, with 55 funds opening new positions, 58 increasing their positions, 33 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

189% more first-time investments, than exits

New positions opened: 55 | Existing positions closed: 19

76% more repeat investments, than reductions

Existing positions increased: 58 | Existing positions reduced: 33

28% more funds holding

Funds holding: 121 → 155 (+34)

18% more capital invested

Capital invested by funds: $1.59B → $1.87B (+$279M)

4.3% more ownership

Funds ownership: 81.95% → 86.26% (+4.3%)

8% less call options, than puts

Call options by funds: $4.12M | Put options by funds: $4.46M

50% less funds holding in top 10

Funds holding in top 10: 4 → 2 (-2)

Holders
155
Holders Change
+34
Holders Change %
+28.1%
% of All Funds
2.24%
Holding in Top 10
2
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-50%
% of All Funds
0.03%
New
55
Increased
58
Reduced
33
Closed
19
Calls
$4.12M
Puts
$4.46M
Net Calls
-$335K
Net Calls Change
+$2.56M

Top Buyers

1
PBA
Paradigm Biocapital Advisors
New York
+$73.5M
2
EC
EcoR1 Capital
California
+$69M
3
State Street
State Street
Massachusetts
+$47M
4
VPC
Vestal Point Capital
New York
+$34M
5
BlackRock
BlackRock
New York
+$30.5M

Top Sellers

1
BI
BVF Inc
California
-$116M
2
O
OrbiMed
New York
-$60.8M
3
RI
RTW Investments
New York
-$37.6M
4
Citadel Advisors
Citadel Advisors
Florida
-$37.2M
5
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$21M
Name Holding Trade Value Shares
Change 		Change in
Stake
Alyeska Investment Group
26
Alyeska Investment Group
Illinois
$8.35M +$298K +6,338 +3%
Northern Trust
27
Northern Trust
Illinois
$8.14M -$357K -7,610 -4%
Point72 Asset Management
28
Point72 Asset Management
Connecticut
$5.72M +$6.41M +136,430 New
Ensign Peak Advisors
29
Ensign Peak Advisors
Utah
$5.57M +$6.24M +133,000 New
Bank of America
30
Bank of America
North Carolina
$5M +$4.5M +95,854 +407%
Bank of New York Mellon
31
Bank of New York Mellon
New York
$4.82M +$3.11M +66,340 +136%
CS
32
Candriam SCA
Luxembourg
$4.69M +$1.5M +31,999 +40%
RPAM
33
Rhenman & Partners Asset Management
Sweden
$4.48M +$110K +2,347 +2%
RCM
34
Ratan Capital Management
Florida
$4.43M +$4.03M +85,757 +429%
Two Sigma Investments
35
Two Sigma Investments
New York
$4.34M -$5.69M -121,119 -54%
D.E. Shaw & Co
36
D.E. Shaw & Co
New York
$4.1M +$2.03M +43,185 +79%
SC
37
Stempoint Capital
New York
$3.89M -$1.35M -28,693 -24%
Morgan Stanley
38
Morgan Stanley
New York
$3.43M -$1.85M -39,433 -33%
Charles Schwab
39
Charles Schwab
California
$3.25M +$1.33M +28,258 +57%
Rafferty Asset Management
40
Rafferty Asset Management
New York
$3.24M +$3.63M +77,246 New
Macquarie Group
41
Macquarie Group
Australia
$3.21M +$779K +16,601 +28%
Tudor Investment Corp
42
Tudor Investment Corp
Connecticut
$2.83M +$2.87M +61,072 +952%
VOYA Investment Management
43
VOYA Investment Management
Georgia
$2.54M +$936K +19,925 +49%
EI
44
EAM Investors
California
$2.33M -$16.7K -355 -0.6%
SCM
45
Soleus Capital Management
Connecticut
$2.32M -$4.8M -102,300 -65%
Voloridge Investment Management
46
Voloridge Investment Management
Florida
$2.31M +$2.59M +55,212 New
UBS Group
47
UBS Group
Switzerland
$2.13M +$1.35M +28,664 +129%
GTC
48
Ghost Tree Capital
New York
$2.09M +$2.35M +50,000 New
SB
49
Samsara BioCapital
California
$1.89M -$6.35M -135,155 -75%
DekaBank Deutsche Girozentrale
50
DekaBank Deutsche Girozentrale
Germany
$1.88M – – –
1
2
3 4 5

JANX Hedge Fund Activity: Q2 2024 in Review

155 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Janux Therapeutics (JANX) for Q2 2024, worth a combined $1.87B — up 18% from $1.59B a quarter earlier.

Buyers outnumbered sellers: 55 funds opened new JANX positions and 19 closed out — a net gain of 36 holders — while 58 added to existing stakes and 33 trimmed.

The largest buyer was Paradigm Biocapital Advisors, opening a new position worth an estimated $73.5M. The largest seller was BVF Inc, cutting an estimated $116M.

  • 155 institutional investors held Janux Therapeutics (JANX) as of Q2 2024, up from 121 in Q1 2024.
  • Funds reported $1.87B of Janux Therapeutics stock for Q2 2024, up 18% quarter-over-quarter.
  • 55 funds opened new Janux Therapeutics positions in Q2 2024 and 19 closed out, a net change of +36 holders.
  • The largest Janux Therapeutics buyer in Q2 2024 was Paradigm Biocapital Advisors, an estimated $73.5M added.
  • The largest Janux Therapeutics seller in Q2 2024 was BVF Inc, an estimated $116M sold.

Based on aggregated 13F filings for Q2 2024.